Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Outstanding (Weighted Average): 2018-2024

Historic Shares Outstanding (Weighted Average) for Arcutis Biotherapeutics (ARQT) over the last 7 years, with Dec 2024 value amounting to $118.6 million.

  • Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) rose 2.58% to $119.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.9 million, marking a year-over-year increase of 2.58%. This contributed to the annual value of $118.6 million for FY2024, which is 25.70% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Shares Outstanding (Weighted Average) of $118.6 million as of FY2024, which was up 25.70% from $94.4 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) ranged from a high of $118.6 million in FY2024 and a low of $50.1 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $94.4 million (2023), whereas its average is $91.3 million.
  • Data for Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 54.91% (in 2023) over the last 5 years.
  • Over the past 5 years, Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $50.1 million in 2020, then climbed by 0.42% to $50.3 million in 2021, then grew by 21.14% to $60.9 million in 2022, then soared by 54.91% to $94.4 million in 2023, then increased by 25.70% to $118.6 million in 2024.